KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy induced nausea and vomiting (RINV): CTRI/2022/01/039723. PMID 42119640 · Radiother Oncol · 2026-Aug The trial meets criteria for oncology, human, randomized, phase III, drug intervention, and original result, but the primary and key secondary endpoints are efficacy outcomes (proportion of patients with nausea/vomiting events), not time-to-event endpoints. Therefore, it is excluded from the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial. PMID 42115521 · Diabetes Obes Metab · 2026-Aug This is a secondary analysis of the SPRINT trial focusing on stroke risk in hypertensive patients with prediabetes and cardiac biomarkers. It is not an oncology study, does not involve a drug-containing intervention (SPRINT's intervention was blood pressure target, not a specific drug), and is not a primary trial result but a subgroup analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study. PMID 42108080 · Diabetes Obes Metab · 2026-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial. PMID 42098550 · Ann Surg Oncol · 2026-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intranasal Ketamine for Existential Distress in Advanced Cancer. PMID 42055096 · J Pain Symptom Manage · 2026-Aug The record is an original report of a randomized controlled trial (RCT) in human oncology patients with a drug intervention (ketamine). However, it fails the time-to-event criterion as all reported outcomes are continuous patient-reported or clinician-rated scales (e.g., MADRS, GAD-7, MQOL) without any Kaplan-Meier, hazard ratio, or time-to-event endpoint (OS, PFS, etc.). Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the publication reports secondary outcomes. Therefore, it is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vision-Related Quality of Life in Geographic Atrophy: Association with Topographic Lesion Distribution. PMID 42031134 · Ophthalmology · 2026-Aug 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Radiological classification of non-anastomotic biliary strictures after liver transplantation. PMID 41995739 · Eur Radiol · 2026-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2/3 randomized clinical trial. PMID 41974353 · Clin Microbiol Infect · 2026-Aug 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer's Disease: Timing and Duration of Adverse Events. PMID 41961243 · Drug Saf · 2026-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Gene Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. PMID 41941952 · Am J Ophthalmol · 2026-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Visualization of Multi-indication Randomized Control Trial Evidence to Support Decision Making in Oncology: A Case Study on Bevacizumab. PMID 41913717 · Med Decis Making · 2026-Aug The record is a meta-analysis/methodological article synthesizing data from multiple trials of bevacizumab; it does not present new primary data from a single Phase III/IIIb or Phase II/III randomized controlled trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial. PMID 41895606 · J Hepatol · 2026-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial. PMID 41880645 · J Urol · 2026-Aug Excluded because the study is single-arm, failing the randomization criterion. All other required criteria (oncology, human, phase 3, time-to-event, drug intervention, original result) are met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant. PMID 41849128 · Drug Saf · 2026-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Integrated psychosocial, sleep, and immunonutritional intervention improves psychological adaptation, sleep disturbance, and inflammatory activation in rectal cancer: a randomized controlled trial. PMID 41714581 · Clin Transl Oncol · 2026-Aug The record describes a randomized, oncology, human trial with a primary time-to-event endpoint (DFS), but the intervention is a non-drug psychosocial, sleep, and nutritional program, not a drug-containing intervention. This violates the 'drug-containing intervention' criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Transarterial Chemoembolization plus Systemic Therapy versus Transarterial Chemoembolization alone for Unresectable, Nonmetastatic Hepatocellular Carcinoma: Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials. PMID 42388346 · Liver Cancer · 2026-Apr-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Limited adoption of thymectomy for nonthymomatous myasthenia gravis. PMID 42182700 · J Thorac Dis · 2026-Apr-30 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Magnetic resonance imaging-based radiomics analysis: predicting vascular invasion in breast invasive ductal carcinoma using different machine learning models. PMID 42180954 · Transl Cancer Res · 2026-Apr-30 The record is a retrospective diagnostic/prognostic study evaluating MRI-based radiomics for predicting lymphovascular invasion in breast cancer. It is not a randomized clinical trial, does not assess a drug intervention, and does not report time-to-event efficacy outcomes.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Association between patient-reported outcomes and pathological response in neoadjuvant chemoimmunotherapy-a post hoc analysis of the TD-FOREKNOW trial. PMID 42170291 · Transl Lung Cancer Res · 2026-Apr-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial. PMID 42122238 · Cancers (Basel) · 2026-Apr-30 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Gastrointestinal and Variceal Bleeding Under Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: Evidence from Trials to Real-World Practice. PMID 42122227 · Cancers (Basel) · 2026-Apr-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide. PMID 42066960 · Transplant Cell Ther · 2026-Apr-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. PMID 42054679 · N Engl J Med · 2026-Apr-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. PMID 41662628 · Blood · 2026-Apr-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies. PMID 41495938 · Clin Infect Dis · 2026-Apr-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial. PMID 41482685 · Clin Infect Dis · 2026-Apr-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Global Disparities and Trends in Radiotherapy for Early-Stage Glottic Cancer. PMID 42187576 · Curr Oncol · 2026-Apr-29 This is a cross-sectional survey of global radiotherapy practices for early-stage glottic cancer, not a report of a randomized controlled trial. It does not involve a drug intervention, does not present time-to-event efficacy results (OS, PFS, DFS, etc.), and is not a primary, interim, or final result report of an oncology clinical trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stroke RiskometerTM mobile phone application improves stroke knowledge in a randomized controlled trial. PMID 42057253 · Int J Stroke · 2026-Apr-29 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of cyclosporine plus luspatercept versus cyclosporine in newly diagnosed non-transfusion-dependent non-severe aplastic anemia: A prospective randomized trial. PMID 42057135 · BMC Med · 2026-Apr-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial. PMID 42056728 · Int J Cancer · 2026-Apr-29 This is a randomized trial in early breast cancer patients, but the primary focus and reported endpoints are on chemotherapy-induced nausea and vomiting (CINV), which is a safety/toxicity outcome, not a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, DFS). The study does not report a Kaplan-Meier curve or hazard ratio for tumor-related efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age. PMID 42054374 · Clin Infect Dis · 2026-Apr-29 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bone Mineral Density Does Not Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial. PMID 42054252 · Dig Dis · 2026-Apr-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk. PMID 42050587 · Trials · 2026-Apr-29 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Eosinophil Counts in Adults With Asthma Treated with Anti-IL-4Rα Rademikibart: Exploratory Analyses in a Randomized Trial. PMID 42061700 · Chest · 2026-Apr-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adaptive design increased success but does not significantly accelerate confirmatory oncology trials. PMID 42054582 · J Natl Cancer Inst · 2026-Apr-28 The record is a methodological analysis of multiple phase III randomized trials, not a primary report of a single drug intervention trial's efficacy results. While it involves oncology, human trials, randomized designs, phase III, and time-to-event endpoints, it does not meet the criterion of being an original result report of a single drug-containing intervention trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study. PMID 42050512 · BMC Med · 2026-Apr-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs. PMID 42050438 · BMC Gastroenterol · 2026-Apr-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
ATOPE study protocol: a randomised controlled trial comparing cystectomy and plasma vapourisation in endometriomas under 6 cm, with an observational arm for sclerotherapy in larger cysts. PMID 42049313 · BMJ Open · 2026-Apr-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma. PMID 42047833 · Cancer Immunol Immunother · 2026-Apr-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A digital twin methodology using retrospective patient data for sample size reduction in Alzheimer's disease clinical trials. PMID 42046101 · Alzheimers Res Ther · 2026-Apr-28 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. PMID 41903215 · JAMA · 2026-Apr-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial. PMID 41628350 · Blood Adv · 2026-Apr-28 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 4 Figure · 8 Panel · risk unclear
An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL. PMID 41587482 · Blood Adv · 2026-Apr-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Preoperative Radiation Therapy and Immediate Breast Reconstruction, a phase 3 randomized controlled trial in the Belgian population (PRADAIIBE): a study protocol. PMID 42046025 · BMC Cancer · 2026-Apr-27 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of fecal microbiota transplantation in reducing recurrence of colorectal adenomas after endoscopic resection: study protocol for a multicenter, open-label, randomized, no-treatment-controlled trial. PMID 42045958 · Trials · 2026-Apr-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Growth and safety evaluation in very low birth weight infants receiving an exclusive human milk diet: a phase III randomized control trial in Japan. PMID 42045666 · J Perinatol · 2026-Apr-27 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Inhaled GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. PMID 42045620 · Lung · 2026-Apr-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1-3 prostate cancer. PMID 42044963 · BMJ Open · 2026-Apr-27 This is a protocol for a randomized trial comparing radiotherapy techniques (brachytherapy vs. external beam radiotherapy) with a spacer gel. It is not a drug-containing intervention, is not reported as Phase III, and does not present results with a time-to-event efficacy endpoint. It is a protocol article without results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of intraoperative use of 20% albumin in combination with Ringer's lactate versus Ringer's lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial). PMID 42044958 · BMJ Open · 2026-Apr-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Conducting a randomized controlled clinical trial on palliative care in patients with glioblastoma - what are the challenges? PMID 42043583 · Support Care Cancer · 2026-Apr-27 The record describes a sub-analysis of the EPCOG trial focusing on trial challenges (screening, attrition, protocol deviations). It is a randomized, human, oncology (glioblastoma) study. However, it is excluded because: 1) The intervention is specialized palliative care (non-drug), not a drug-containing intervention. 2) No time-to-event efficacy endpoint (e.g., OS, PFS) or its analysis (Kaplan-Meier, HR) is reported or signaled in the abstract. 3) The report type is a secondary analysis of trial conduct challenges, not the primary efficacy results of the trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -